China NT Pharma Terminates License Agreement with Abcentra for Monoclonal Antibody Technology; Shares Fall 10%

MT Newswires Live07-22

China NT Pharma Group (HKG:1011) (HKG:2199) subsidiary Green-Life Technology (Hong Kong) terminated its acquisition agreement with licensor Abcentra, according to a Friday filing with the Hong Kong Stock Exchange.

The now-terminated agreement should have seen Green-Life Technology granted a perpetual commercialization license for Abcentra's monoclonal antibody technology for the treatment of atherosclerotic cardiovascular conditions, psoriasis, and rheumatoid arthritis, among other conditions, according to a June 2022 filing.

Both parties could not agree on the delays in the research and development and timetable of the agreement, as well as China NT Pharma's shift in focus to bone health, hence the termination, the Friday filing said.

No license fees have been given to Abcentra, the filing said.

Shares plunged 10% in Hong Kong during Monday's afternoon trading.

Price (HKD): $0.30, Change: $-0.04, Percent Change: -10.45%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453739632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-22 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453739632","market":"nz","top_or_hot":-1,"title":"China NT Pharma Terminates License Agreement with Abcentra for Monoclonal Antibody Technology; Shares Fall 10%","media":"MT Newswires Live","content":"<html><body><p> China NT Pharma Group (HKG:1011) (HKG:2199) subsidiary Green-Life Technology (Hong Kong) terminated its acquisition agreement with licensor Abcentra, according to a Friday filing with the Hong Kong Stock Exchange.</p><p>The now-terminated agreement should have seen Green-Life Technology granted a perpetual commercialization license for Abcentra's monoclonal antibody technology for the treatment of atherosclerotic cardiovascular conditions, psoriasis, and rheumatoid arthritis, among other conditions, according to a June 2022 filing.</p><p>Both parties could not agree on the delays in the research and development and timetable of the agreement, as well as China NT Pharma's shift in focus to bone health, hence the termination, the Friday filing said.</p><p>No license fees have been given to Abcentra, the filing said.</p><p>Shares plunged 10% in Hong Kong during Monday's afternoon trading.</p><p>Price (HKD): $0.30, Change: $-0.04, Percent Change: -10.45%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China NT Pharma Terminates License Agreement with Abcentra for Monoclonal Antibody Technology; Shares Fall 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina NT Pharma Terminates License Agreement with Abcentra for Monoclonal Antibody Technology; Shares Fall 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China NT Pharma Group (HKG:1011) (HKG:2199) subsidiary Green-Life Technology (Hong Kong) terminated its acquisition agreement with licensor Abcentra, according to a Friday filing with the Hong Kong ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453739632","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453739632","pubTimestamp":1721629035,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China NT Pharma Group   subsidiary Green-Life Technology  terminated its acquisition agreement with licensor Abcentra, according to a Friday filing with the Hong Kong Stock Exchange.The now-terminated agreement should have seen Green-Life Technology granted a perpetual commercialization license for Abcentra's monoclonal antibody technology for the treatment of atherosclerotic cardiovascular conditions, psoriasis, and rheumatoid arthritis, among other conditions, according to a June 2022 filing.Both parties could not agree on the delays in the research and development and timetable of the agreement, as well as China NT Pharma's shift in focus to bone health, hence the termination, the Friday filing said.No license fees have been given to Abcentra, the filing said.Shares plunged 10% in Hong Kong during Monday's afternoon trading.Price : $0.30, Change: $-0.04, Percent Change: -10.45%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK1227":"服装、服饰与奢侈品","02199":"维珍妮","HKD":"尚乘数科","BK1191":"制药","BK4585":"ETF&股票定投概念","BK4588":"碎股","01011":"泰凌医药","BK4526":"热门中概股"},"translate_title":"中国泰凌医药终止与Abcentra的单克隆抗体技术许可协议；股价下跌10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02199":1,"HKD":1,"01011":0.9},"content_text":"China NT Pharma Group (HKG:1011) (HKG:2199) subsidiary Green-Life Technology (Hong Kong) terminated its acquisition agreement with licensor Abcentra, according to a Friday filing with the Hong Kong Stock Exchange.The now-terminated agreement should have seen Green-Life Technology granted a perpetual commercialization license for Abcentra's monoclonal antibody technology for the treatment of atherosclerotic cardiovascular conditions, psoriasis, and rheumatoid arthritis, among other conditions, according to a June 2022 filing.Both parties could not agree on the delays in the research and development and timetable of the agreement, as well as China NT Pharma's shift in focus to bone health, hence the termination, the Friday filing said.No license fees have been given to Abcentra, the filing said.Shares plunged 10% in Hong Kong during Monday's afternoon trading.Price (HKD): $0.30, Change: $-0.04, Percent Change: -10.45%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453739632"}